Intelligence Platform

Patents

Browse 89 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 10308941

Compositions and methods for inhibiting gene expression of factor XII

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10294474

Targeting ligands

Arrowhead Pharmaceuticals, Inc. · Granted Tue May 21 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10287582

Organic compositions to treat HSF1-related diseases

Arrowhead Pharmaceuticals, Inc. · Granted Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10273482

dsRNA for treating viral infection

Arrowhead Pharmaceuticals, Inc. · Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10246709

Targeting ligands for therapeutic compounds

Arrowhead Pharmaceuticals, Inc. · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10240153

Organic compositions to treat APOC3-related diseases

Arrowhead Pharmaceuticals, Inc. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10138483

Transferrin/transferrin receptor-mediated siRNA delivery

Arrowhead Pharmaceuticals, Inc. · Granted Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10130651

RNAi Therapy for Hepatitis B Virus Infection

Arrowhead Pharmaceuticals, Inc. · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10081811

Organic compositions to treat Beta-ENaC-related diseases

Arrowhead Pharmaceuticals, Inc. · Granted Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10047361

Disulfide-containing alkyne linking agents

Arrowhead Pharmaceuticals, Inc. · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10023862

Organic compositions to treat beta-catenin-related diseases

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10022456

Reversibly masked polymers

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10006025

Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10005815

Biologically cleavable tetrapeptide linking agents

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9976141

Compositions and methods for inhibiting gene expression of Hif2alpha

Arrowhead Pharmaceuticals, Inc. · Granted Tue May 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9938531

Compositions and methods for inhibiting expression of RRM2 genes

Arrowhead Pharmaceuticals, Inc. · Granted Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9932584

Interfering RNA delivery system and uses thereof

Arrowhead Pharmaceuticals, Inc. · Granted Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9914927

RNAi inhibition of alpha-ENaC expression

Arrowhead Pharmaceuticals, Inc. · Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9868949

Organic compositions to treat EPAS1-related diseases

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9803201

Disulfide-containing alkyne linking agents

Arrowhead Pharmaceuticals, Inc. · Granted Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9803205

Compositions and methods for inhibiting gene expression of factor XII

Arrowhead Pharmaceuticals, Inc. · Granted Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9796756

Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA

Arrowhead Pharmaceuticals, Inc. · Granted Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9795684

Interfering RNA delivery system and uses thereof

Arrowhead Pharmaceuticals, Inc. · Granted Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9765340

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular

Arrowhead Pharmaceuticals, Inc. · Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted